Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 461.45 INR
Change Today -2.45 / -0.53%
Volume 328.2K
BIOS On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:05 AM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

biocon ltd (BIOS) Snapshot

Open
464.95
Previous Close
463.90
Day High
467.00
Day Low
459.60
52 Week High
07/4/14 - 553.70
52 Week Low
01/7/15 - 402.30
Market Cap
92.3B
Average Volume 10 Days
586.2K
EPS TTM
25.06
Shares Outstanding
200.0M
EX-Date
04/9/15
P/E TM
18.4x
Dividend
5.00
Dividend Yield
2.17%
Current Stock Chart for BIOCON LTD (BIOS)

Related News

No related news articles were found.

biocon ltd (BIOS) Related Businessweek News

No Related Businessweek News Found

biocon ltd (BIOS) Details

Biocon Limited, an integrated healthcare company, develops and sells biotechnology products for the pharmaceutical sector in India and internationally. It offers active pharmaceutical ingredients, including cardiovascular agents, anti-obesity agents, immunosuppressants, and narrow spectrum antibiotics; and biosimilars comprising human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, filgrastim, streptokinase, and monoclonal antibodies. The company also provides branded formulations in the areas of cardiology, diabetology, oncology, nephrology, cardiology, immunotherapy, and comprehensive care; and out-licensing services. In addition, it offers contract manufacturing services, including mammalian cell culture fermentation, microbial cell culture fermentation, and synthetic chemistry to small-to-medium sized pharmaceutical and biotech companies; undertakes clinical research activities on discovering new biomarkers; and provides integrated contract research services to support discovery and development, for small and large molecules. The company’s principal brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It serves its customers in approximately 85 countries. The company was founded in 1978 and is headquartered in Bengaluru, India.

7,528 Employees
Last Reported Date: 06/23/15
Founded in 1978

biocon ltd (BIOS) Top Compensated Officers

Chief Executive Officer, Joint Managing Direc...
Total Annual Compensation: 25.5M
Founder, Chairman, Managing Director, Member ...
Total Annual Compensation: 14.7M
Chief Financial Officer and President of Fina...
Total Annual Compensation: --
President of Research & Development
Total Annual Compensation: --
Vice Chairman, Member of Share Transfer Commi...
Total Annual Compensation: 14.8M
Compensation as of Fiscal Year 2015.

biocon ltd (BIOS) Key Developments

Biocon Limited Announces Two Biocon Biosimilar Drugs Enter Global Clinical Trials

Biocon Ltd. announced that two biosimilar drug molecules developed by it to treat cancer and rheumatoid arthritis had entered global phase 3 clinical trials, which entail testing on patients to assess effectiveness and safety. The two molecules, pegfilgrastim and adalimumab, were developed in partnership with Mylan NV. Pegfilgrastim is used to treat cancer. Biosimilars are generic versions of biological drugs that are not possible to copy exactly and require clinical trials to establish that they are safe and effective. The US Food and Drug Administration (FDA) approved the first biosimilar of filgrastim in March under the biosimilars pathway, established by the 2009 Biologics Price Competition and Innovation Act (BPCIA), paving the way for more biosimilars to hit the world's largest market for medicines. The phase 3 trial for its breast cancer drug trastuzumab is progressing in more than 100 sites around the world. Trastuzumab is the biosimilar version of Roche Holding AG's monoclonal antibody Herceptin, used in the treatment of breast cancer based on HER2-positive subtype gene mutation. Biocon sells Trastuzumab under brand name CANMAb in India. The initial test of the phase 3 trial for bevacizumab or biosimilar version of Roche's Avastin is also underway.

Biocon Limited Reports Audited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015; Provides Capex Guidance for the Next Five Years; Provides Tax Rate Guidance for the Year 2015

Biocon Limited reported audited consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 8,303.8 million against INR 7,225.9 million for the same period a year ago. Total income from operations (net) was INR 8,376.8 million against INR 7,285.3 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 1,267.1 million against INR 1,215.5 million for the same period a year ago. Profit from ordinary activities before tax was INR 2,486.0 million against INR 1,380.6 million for the same period a year ago. Net profit was INR 2,168.0 million against INR 1,189.1 million for the same period a year ago. Earnings per diluted share (not annualized) were INR 10.08 against INR 5.69 for the same period a year ago. Total revenue was INR 8,540 million against INR 7,460 million for the same period a year ago. EBITDA was INR 2,020 million against INR 1,930 million for the same period a year ago. The drop in EBITDA is largely due to increased R&D spends both in fourth quarter as well as the full year. For the year, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 30,599.7 million against INR 28,527.2 million for the same period a year ago. Total income from operations (net) was INR 30,898.1 million against INR 28,773.1 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 4,748.9 million against INR 4,834.9 million for the same period a year ago. Profit from ordinary activities before tax was INR 6,241.3 million against INR 5,376.6 million for the same period a year ago. Net profit was INR 5,284.7 million against INR 4,307.5 million for the same period a year ago. Earnings per diluted share (not annualized) were INR 24.87 against INR 20.82 for the same period a year ago. Total revenue was INR 31,430 million against INR 29,330 million for the same period a year ago. EBITDA was INR 7,490 million against INR 7,430 million for the same period a year ago. Full year, adjusted net profit was INR 4,020 million. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 5,604.7 million against INR 5,375.7 million for the same period a year ago. Total income from operations (net) was INR 5,833.8 million against INR 5,714.3 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 703.6 million against INR 882.4 million for the same period a year ago. Profit from ordinary activities before tax was INR 623.3 million against INR 990.9 million for the same period a year ago. Net profit was INR 477.9 million against INR 867.4 million for the same period a year ago. Earnings per diluted share (after giving impact of scheme of merger for earlier year) were INR 2.39 against INR 4.37 for the same period a year ago. For the year, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 21,417.9 million against INR 20,980.7 million for the same period a year ago. Total income from operations (net) was INR 22,416.0 million against INR 22,025.0 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 3,018.5 million against INR 3,488.2 million for the same period a year ago. Profit from ordinary activities before tax was INR 4,282.8 million against INR 4,085.1 million for the same period a year ago. Net profit was INR 3,612.2 million against INR 3,243.1 million for the same period a year ago. Earnings per diluted share (after giving impact of scheme of merger for earlier year) were INR 18.06 against INR 16.62 for the same period a year ago. For the next five years, the company to invest in couple of greenfield projects. Apart from that, the company's capex, which the company call maintenance capex, would be around INR 2,000 million to INR 2,500 million per year. For the fiscal year 2016, the company expects tax rate to be 20% to 22%.

Biocon Limited Receives Approval for Insulin Glargine through its Partner PISA Farmaceutica

Biocon Limited announced that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PISA Farmaceutica (PISA).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOS:IN 461.45 INR -2.45

BIOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $5.10 USD +0.11
Cambrex Corp $44.24 USD -0.61
Croda International PLC 2,768 GBp -10.00
Divi's Laboratories Ltd 1,853 INR -13.05
Piramal Enterprises Ltd 955.55 INR +23.45
View Industry Companies
 

Industry Analysis

BIOS

Industry Average

Valuation BIOS Industry Range
Price/Earnings 18.3x
Price/Sales 2.9x
Price/Book 2.7x
Price/Cash Flow 12.6x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCON LTD, please visit www.biocon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.